Literature DB >> 23847364

The KRAS-PDEδ interaction is a therapeutic target.

.   

Abstract

Targeting the KRAS-PDEδ interaction inhibits KRAS-dependent signaling and tumor growth.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23847364     DOI： 10.1158/2159-8290.CD-RW2013-116

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  1 in total

1.  Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.

Authors:  P Dietrich; S Kuphal; T Spruss; C Hellerbrand; A K Bosserhoff
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.